Arcellx’s (ACLX) Hold Rating Reaffirmed at Needham & Company LLC

Arcellx (NASDAQ:ACLX)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a report released on Monday,Benzinga reports.

Several other equities research analysts have also issued reports on ACLX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. Wells Fargo & Company restated an “equal weight” rating and set a $115.00 price objective on shares of Arcellx in a research report on Monday. Canaccord Genuity Group reiterated a “buy” rating and issued a $130.00 target price on shares of Arcellx in a research report on Monday, December 8th. Wolfe Research assumed coverage on Arcellx in a research report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Finally, Rothschild & Co Redburn lowered Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 price target for the company. in a research note on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Arcellx presently has a consensus rating of “Hold” and an average price target of $111.83.

Arcellx Stock Performance

Arcellx stock traded up $49.80 during midday trading on Monday, hitting $113.91. 15,227,275 shares of the company’s stock were exchanged, compared to its average volume of 1,220,206. The company has a market cap of $6.59 billion, a P/E ratio of -28.98 and a beta of 0.36. The stock has a 50-day moving average price of $66.98 and a two-hundred day moving average price of $74.77. Arcellx has a 52-week low of $47.86 and a 52-week high of $114.26.

Insider Activity at Arcellx

In other news, insider Christopher Heery sold 7,437 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total value of $487,197.87. Following the completion of the sale, the insider owned 29,631 shares of the company’s stock, valued at approximately $1,941,126.81. The trade was a 20.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 19,450 shares of company stock valued at $1,283,477 in the last quarter. 8.35% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arcellx

Several institutional investors and hedge funds have recently bought and sold shares of ACLX. MAI Capital Management bought a new stake in Arcellx in the third quarter valued at approximately $26,000. CWM LLC increased its stake in shares of Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after buying an additional 251 shares during the period. State of Wyoming bought a new stake in Arcellx during the 2nd quarter valued at $28,000. Ramirez Asset Management Inc. purchased a new stake in Arcellx during the 3rd quarter valued at $41,000. Finally, PNC Financial Services Group Inc. grew its holdings in Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock worth $49,000 after acquiring an additional 486 shares during the last quarter. 96.03% of the stock is currently owned by institutional investors.

Key Headlines Impacting Arcellx

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for an implied equity value of roughly $7.8B — $115 cash per share plus a $5 CVR — signaling strong strategic validation of Arcellx’s oncology program and driving the stock higher. Gilead Sciences to Acquire Arcellx (Business Wire)
• Positive Sentiment: Multiple major outlets (Reuters) confirm the deal terms and valuation, reinforcing market confidence that the offer is credible and will likely close subject to approvals. Gilead to acquire cancer therapy developer Arcellx (Reuters)
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating and set a $115 price target (roughly in line with the deal price), a stance that neither materially alters the takeover outlook nor pushes the stock above the offer level. ACLX rating at Wells Fargo (The Fly)
• Neutral Sentiment: Coverage pieces explaining the rally (MSN, Invezz) make clear the price move is driven by the buyout rather than new clinical data; useful for investors assessing whether the market reaction reflects a takeover premium versus underlying fundamentals. Why is Arcellx stock up 80% today? (Invezz)
• Neutral Sentiment: Recent hedge fund activity: Perceptive Advisors sold ~1.0M ACLX shares in Q4, a reminder that institutional positioning can shift quickly ahead of deal news. Perceptive Advisors sale (The Motley Fool)
• Negative Sentiment: An investor-rights firm, Halper Sadeh LLC, has opened an investigation into whether Arcellx shareholders are receiving a fair price, which could signal potential litigation or pushback that delays closing or prompts supplementary disclosures. Halper Sadeh investigation (Business Wire)

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.